EU/3/18/2005

About

On 21 March 2018, orphan designation (EU/3/18/2005) was granted by the European Commission to Quintiles Ireland Limited, Ireland, for tazemetostat for the treatment of follicular lymphoma.

In May 2018, Quintiles Ireland Limited changed name to IQVIA RDS Ireland Limited.

Key facts

Active substance
Tazemetostat
Disease / condition
Treatment of follicular lymphoma
Date of decision
21/03/2018
Outcome
Positive
Orphan decision number
EU/3/18/2005

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

IQVIA RDS Ireland Limited
Estuary House
East Point Business Park
Fairview
Dublin 3
Ireland
Tel. +353 1 819 51 00
E-mail: Irina.Mikhailenko@iqvia.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating